Novel inhibitors | DC Chemicals

Cat. No.	Product name	CAS No.
DCC4020	Pc407-ws Water-soluble novel potential COX-2 inhibitor	1242169-24-9
DCC4021	Pcb153 Non-dioxin-like (NDL) congener	35065-27-1
DCC4022	Pcb-te2p Novel Chelator for Cu-64
DCC4023	Pcc-0105002 Novel PSD95-nNOS inhibitor, disrupting the PSD95-nNOS interaction, attenuating neuropathic pain, decreasing SNL-induced spinal dorsal horn WDR neuron hyperexcitation
DCC4024	Pcc0208018 Novel activator of effector T cells, enhancing T cell proliferation and activation to release interferon gamma (IFN-γ) and interleukin-2 (IL-2) without blocking the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) binding and not dire	1673534-73-0
DCC4025	P-cf3-diepp Novel α7 nAChR weak partial agonist, showing antinociceptive and anti-inflammatory properties
DCC4026	p-chloro-diphenyl Diselenide Organoselenium compound with antidepressant-like and memory enhancer actions	20541-49-5
DCC4027	pcm126 Potent antagonist of the series disrupting EphA2-ephrinA1 interaction, blocking EphA2 phosphorylation in prostate cancer cells at low	192876-13-4
DCC4028	p-come 102 Highly selective α1L adrenaline receptor agonist	1354932-35-6
DCC4029	Pcpma-(1r,2r)-22e Novel potent dopamine D3R agonist (Ki=4.1nM)
DCC4030	Pcpma-(1r,2r)-30q Novel potent and selective dopamine D3R partial agonist
DCC4031	Pcpma-(1s,2s)-22e Novel potent dopamine D3R antagonist
DCC4032	Pcsk9 Modulator Novel modulator of proprotein convertase subtilisin kexin like type 9 (PCSK9)
DCC4033	Pcsk9-in-4d Novel PCSK9 mRNA translation inhibitor
DCC4034	Pcsk9-in-4g Novel PCSK9 mRNA translation inhibitor
DCC4035	Pcsk9-in-8b Novel liver-targeted inhibitor of ribosomal synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9)
DCC4036	Pd-1 Inhibitor 16 Novel inhibitor of PD-I/PD-L1 interaction to be used as a negative immune checkpoint regulatory and antineoplastic agent	2005454-12-4
DCC4037	Pd-1/pd-l1 Antagonist D2 Novel potent PD-1/PD-L1 antagonist (IC50 of 16.17 nM), activating the antitumor immunity of T cells efficiently in PBMCs
DCC4038	Pd-1/pd-l1 Inhibitor 17 Novel bifunctional inhibitor of PD-1/PD-L1 interactions, promoting dimerization, internalization, and degradation of PD-L1, suppressing tumor growth in vivo by activating antitumor immunity
DCC4039	Pd-1/pd-l1 Inhibitor A30 Novel Potent Inhibitor of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
DCC4040	Pd-1/pd-l1 Inhibitor Ch1 Novel inhibitor of PD-1/PD-L1 (IC 50 value of 56.58 nM), dose-dependently promoting HepG2 cell death in a co-culture model of HepG2/hPD-L1 and Jurkat T cells, effectively inhibiting tumor growth (TGI of 76.4% at 90 mg/kg) in an immune checkpoint humanized
DCC4041	Pd-1/pd-l1 Inhibitor P18 Novel potent programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor (IC50 9.1 nM)